Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%
Earnings Routine +

HLS Therapeutics Announces Q1 2026 Financial Results

HLS Therapeutics Debt Reduction and NILEMDO Launch Execution Validate Operational Turnaround Despite Modest Revenue Growth

By The Northwire Desk — AI Analysis May 15, 2026 · 07:00 HLS · 4.67 HLS THERAPEUTICS INC. J
Executive Summary
  • HLS Therapeutics reported Q1 2026 financial results on May 15, 2026.
  • Revenue increased 2% year-over-year to $12.9 million, driven by Vascepa sales growth of 15%.
  • Net loss narrowed significantly to ($2.3) million from ($4.4) million in Q1 2025.
  • Cash from operations surged 80% year-over-year to $6.4 million.
  • Net debt reduced by 32% year-over-year to $31.9 million, with $5.1 million in principal repayments made during the quarter.
  • NILEMDO™ launched commercially in April 2026; early weekly sales are running ahead of forecast.
  • Private payers Canada Life and Sun Life added NILEMDO without prior authorization.
  • Full-year 2026 guidance reaffirmed: Revenue $56–60 million, Adjusted EBITDA $18.5–21 million.
Material Impact
  • The Q1 results confirm the operational improvements highlighted in the Fiscal 2025 earnings released March 12, 2026.
  • Profitability improvement is notable (loss narrowed by ~47%), but revenue growth remains modest (+2%).
  • Debt reduction trajectory continues from FY25 ($17.8M repaid) to Q1 2026 ($5.1M repaid), strengthening the balance sheet without dilution.
  • NILEMDO launch execution is positive ("ahead of forecast"), but this was anticipated following the March announcement of the April launch date.
  • Reaffirmation of guidance suggests management sees no immediate need to revise expectations upward despite better-than-expected cash flow and loss reduction.
  • The news validates the strategy rather than introducing a new catalyst, making it incremental relative to previous market expectations set in March 2026.
HLS · Price
Company Overview
  • Company: HLS Therapeutics Inc., a Canadian pharmaceutical company focused on cardiovascular and psychiatric medicines.
  • Flagship Project 1 (Vascepa): Prescription omega-3 acid ethyl esters for cardiovascular health; driving the majority of revenue growth (+15% YoY).
  • Flagship Project 2 (NILEMDO™): Bempedoic acid, a non-statin oral therapy for LDL-C reduction. Launched April 2026 in Canada following Health Canada approval Nov 2025.
  • Flagship Project 3 (Clozaril): Antipsychotic medication; sales declining (-4% Q3 2025) but stabilizing in Ontario volumes as of March/April 2026.
  • Pipeline: NEXLIZET® (bempedoic acid/ezetimibe combination) targeted for H1 2027 launch pending regulatory clearance.
Read the original news release →

More from HLS THERAPEUTICS INC. J

Mar 12, 2026 · 06:30

HLS Therapeutics Announces Fiscal 2025 Financial Results

Earnings Mar 05, 2026 · 17:48

HLS Therapeutics launches Nilemdo in Canada

Regulatory Mar 05, 2026 · 07:00

HLS Therapeutics Announces NILEMDOTM (bempedoic acid) is now available in Canada for the Reduction of LDL-Cholesterol in Patients at Risk of Cardiovascular Disease

Other Nov 18, 2025 · 12:38

HLS gets approval for Nilemdo; Nezlizet needs more data

Regulatory Nov 18, 2025 · 07:00

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO(TM) for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Regulatory Nov 13, 2025 · 06:30

HLS Therapeutics Announces Q3 2025 Financial Results

Earnings